Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 334 · FY2023 643 · FY2024 19 — 3-yr total 996
Georgian medical diagnostic / laboratory services company affiliated with the international Human Diagnostic network.
Group parent — controls 1 company · ownership
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 8,954 | 9,038 | 14,755 | 23,687 | 14,197 | 12,301 | 13,112 | +6.6% | |
| Total COGS | 9,549 | 6,031 | 9,573 | 15,099 | 9,060 | 7,672 | 8,245 | -2.4% |
| Gross Profit | 595 | 3,007 | 5,182 | 8,588 | 5,136 | 4,629 | 4,867 | nmf |
| Gross Margin | 6.6% | 33.3% | 35.1% | 36.3% | 36.2% | 37.6% | 37.1% | |
| Other Operating Income | 0 | 0 | 0 | 0 | 147 | 448 | 153 | +2.1% |
| 0 | 1,268 | 2,776 | 2,760 | 2,825 | 3,391 | 3,472 | +22.3% | |
| EBITDA | 595 | 1,739 | 2,405 | 5,828 | 2,458 | 1,686 | 1,548 | nmf |
| EBITDA Margin | 6.6% | 19.2% | 16.3% | 24.6% | 17.3% | 13.7% | 11.8% | |
| Total D&A | 0 | 52 | 87 | 246 | 440 | 536 | 544 | +59.9% |
| EBIT / Operating Income | 595 | 1,687 | 2,318 | 5,583 | 2,018 | 1,150 | 1,004 | nmf |
| Total Interest Income | 0 | 38 | 44 | 0 | 0 | 0 | 0 | +14.2% |
| Total Interest Expense | 0 | 108 | 0 | 0 | 0 | 0 | 252 | +18.5% |
| 0 | 46 | 0 | 0 | 0 | 0 | 0 | ||
| Profit Before Tax | 595 | 1,572 | 2,362 | 5,583 | 2,018 | 1,150 | 753 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 59 | 0 | 3 | -78.3% |
| Net Profit / (Loss) | 595 | 1,572 | 2,250 | 5,490 | 1,807 | 1,150 | 750 | nmf |
| Net Margin | 6.6% | 17.4% | 15.3% | 23.2% | 12.7% | 9.3% | 5.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.